Lebrest 2.5mg tablets

Ferron Par Pharmaceuticals

Ingredients in every tablet

Letrozole 2.5 mg

Each package contains

3 blisters of 10 tablets

Other details

Dosage form:Tablet; coated
Flavour: None

W.H.O. classification

ATC Level 1: L - Antineoplastic and immunomodulating agents
ATC Level 2: L02 - Endocrine Therapy Antineoplastic and Immunomodulating Agents
ATC Level 3: L02B - Hormone Antagonists and Related Agents

Warnings

Pregnancy

NOT SAFEThis item is not safe for use during pregnancy.

Lactation

NOT SAFEThis item is not safe for use during lactation.

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

NOT SAFEThis item should not be used while operating heavy machinery.

Available in

Indonesia

Dosage information

18 YEARS OLD AND ABOVE
Adults and elderly patients. The recommended dose of letrozole is 2.5 mg once daily. In the adjuvant and extended adjuvant setting, treatment with letrozole should continue for 3 years or until tumor relapse occurs, whichever comes first. In patients with metastatic disease, treatment with letrozole should continue until tumor progression is evident. No dose adjustment is required for elderly patients. Patients with hepatic and/or renal impairment. No dosage adjustment is required for patients with mild to moderate hepatic impairment or renal impairment (creatinine clearance ≥10 ml/min).

Food does not affect the absorption of letrozole and the drug may be
administered without regard to meals.

HEPATIC AND/OR RENAL IMPAIRMENT
No dosage adjustment is required for patients with mild to moderate hepatic
impairment or renal impairment (creatinine clearance 10 ml/min).

Indication

– Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer Extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. Treatment in postmenopausal women with hormone-dependent advanced breast cancer. Treatment of advanced breast cancer in women with natural or artificially induced postmenopausal status, who have previously been treated with antiestrogens. Preoperative therapy in postmenopausal women with localized hormone receptor positive breast cancer, to allow subsequent breast-conserving surgery in women not originally considered candidates for this type of surgery. Subsequent treatment after surgery should be in accordance with standard of care.

Disclaimer

The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for informational purposes only. This tool may not cover all possible drug interactions or all warnings or alerts. Please check with a physician if you have health questions or concerns about interactions or go to the appropriate government authority for a comprehensive list of medical warnings. Although we attempt to provide accurate and up-to-date information, no guarantee is made to that effect.

All of the content present on this website, including written text, photographs, videos, graphics, and other resources we might include (these will fall under the collective term of “website”), is meant to educate and should not be perceived as a substitution for professional medical advice, diagnosis or treatment. You should not resort to the website information to arrive at a diagnosis or treatment solution for your health problems or various medical conditions. It does not replace medical care, provided by a medical specialist. In the situation, you have specific symptoms and you might suspect that you are suffering from a medical problem, it is for the best to consult your physician.